Holen Sie sich die Stockscreener-App
27.73
1.49%
0.4066
Schlusskurs vom Vortag:
$27.32
Offen:
$27.24
24-Stunden-Volumen:
3,928
Relative Volume:
1.12
Marktkapitalisierung:
$2.56B
Einnahmen:
$80.00M
Nettoeinkommen (Verlust:
$-172.98M
KGV:
-14.28
EPS:
-1.9419
Netto-Cashflow:
$164.80M
1W Leistung:
+19.77%
1M Leistung:
+19.82%
6M Leistung:
-30.44%
1J Leistung:
+32.35%
1-Tages-Spanne:
$27.24
$28.06
1-Wochen-Bereich:
$23.74
$28.06
52-Wochen-Spanne:
$17.55
$48.45
Ascentage Pharma Group International Adr Stock (AAPG) Company Profile
Firmenname
Ascentage Pharma Group International Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare AAPG vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AAPG
Ascentage Pharma Group International Adr
|
27.41 | 2.55B | 80.00M | -172.98M | 164.80M | -1.9419 |
VRTX
Vertex Pharmaceuticals Inc
|
433.68 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.51 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.60 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
331.03 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.76 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Ascentage Pharma Group International Adr Stock (AAPG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-12 | Fortgesetzt | BTIG Research | Buy |
| 2026-01-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2025-12-04 | Eingeleitet | Oppenheimer | Outperform |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-10 | Eingeleitet | BTIG Research | Buy |
| 2025-11-05 | Eingeleitet | Piper Sandler | Overweight |
| 2025-03-27 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Ascentage Pharma Group International Adr Aktie (AAPG) Neueste Nachrichten
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap UpShould You Buy? - MarketBeat
Ascentage Pharma Group International (NASDAQ:AAPG) Trading Up 12%Should You Buy? - MarketBeat
Why nCino Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Sahm
Ascentage Pharma Group International (NASDAQ:AAPG) Sees Large Volume IncreaseHere's Why - MarketBeat
Ascentage Pharma Group InternationalUnsponsored ADR (NASDAQ:AAPG) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Truist Financial Remains a Buy on Ascentage Pharma Group International Unsponsored ADR (AAPG) - The Globe and Mail
BTIG Remains a Buy on Ascentage Pharma Group International Unsponsored ADR (AAPG) - The Globe and Mail
Earnings Scheduled For March 25, 2026 - Sahm
Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates - GlobeNewswire Inc.
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Up 20.3%Should You Buy? - marketbeat.com
Short Interest in Ascentage Pharma Group InternationalUnsponsored ADR (NASDAQ:AAPG) Increases By 546.9% - MarketBeat
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap DownTime to Sell? - MarketBeat
Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 7.7%Here's Why - MarketBeat
Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026 - Sahm
Ascentage Pharma Sets March 25 Board Meeting on 2025 Results and Potential Final Dividend - TipRanks
Ascentage Pharma Sets March 25, 2026 Date to Unveil 2025 Unaudited Results and Business Update - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Abivax SA Sponsored ADR (ABVX), Irhythm Technologies (IRTC) - The Globe and Mail
Ascentage Pharma Ramps Up Investor Outreach With Three U.S. Conferences - TipRanks
Rodman & Renshaw Initiates Ascentage Pharma Group International (AAPG) with Buy Rating, $48 Target - Finviz
Ascentage Pharma to Present at Guggenheim Biotech Summit as Late-Stage Oncology Pipeline Expands - The Globe and Mail
Ascentage Pharma Wins China IND Clearance for Next-Gen BTK Degrader APG-3288 - TipRanks
Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 - Sahm
Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Resmed (RMD) and Sanofi (OtherSNYNF) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Sees Significant Increase in Short Interest - Defense World
Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Nurix Therapeutics (NRIX) - The Globe and Mail
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Update - Defense World
Ascentage Pharma Details 2026 Global Innovation Strategy at J.P. Morgan Healthcare Conference - TipRanks
Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference - markets.businessinsider.com
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Regeneron (REGN) and Progyny (PGNY) - The Globe and Mail
LENZ Therapeutics (LENZ) Receives a Buy from Piper Sandler - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: BeOne Medicines (ONC) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Finanzdaten der Ascentage Pharma Group International Adr-Aktie (AAPG)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):